General
Preferred name
LEVETIRACETAM
Synonyms
ETIRACETAM ()
UCB L059 ()
SIB-S1 ()
LEVETIRACETAM102767-28-2 ()
UCB-L059, SIB-S1 ()
Levetiracetam (UCB-L059) ()
Keppra Xr ()
AGB-101 ()
Levetiracetam accord ()
Spritam ()
Keppra ()
UCB-L059 ()
N03AX14 ()
Desitrend ()
Levetiracetam sun ()
NSC-760119 ()
Levetiracetam teva ()
Levetiracetam hospira ()
Matever ()
Levetiracetam actavis ()
Levetiracetam ratiopharm ()
Levetiracetam In Sodium Chloride ()
UCB-22059 ()
Levetiracetam actavis group ()
Elepsia ()
Levetiracetame ()
Elepsia XR ()
UCB 22059 ()
Levetiracetam-d6 ()
P&D ID
PD001324
CAS
102767-28-2
1133229-30-7
Tags
available
drug
Approved by
FDA
PMDA
EMA
First approval
1999
Drug indication
Fibromyalgia
Epilepsy
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION In addition to being assigned an INN in its own right, levetiracetam is the biologically active enantiomer of racemic formulation etiracetam, also assigned an INN.
Levetiracetam is the active compound in SpritamĀ®, the first 3D printed pill to be approved by the US FDA (in August 2015). (GtoPdb)
PRICE 29
DESCRIPTION p53-stabilizing agent (Tocris Bioactive Compound Library)
DESCRIPTION Antiepileptic; binds SV2A (Tocriscreen Plus)
DESCRIPTION Anticonvulsant; antiepileptic; exact mechanism of action is unclear but may be related to a synaptic vesicle protein. (LOPAC library)
DESCRIPTION Levetiracetam is an antiepileptic agent that binds to the synaptic vesicle protein SV2A. It is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. (Enamine Bioactive Compounds)
DESCRIPTION Levetiracetam (SIB-S1) is a relatively unique anticonvulsant that is typically used in combination with other antiepileptic medications for partial onset seizures. Levetiracetam has been linked to rare instances of serum aminotransferase and alkaline phosphatase elevations during treatment and to rare cases of clinically apparent drug induced liver disease. (TargetMol Bioactive Compound Library)
Compound Sets
33
Axon Medchem Screening Library
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
LOPAC library
Mcule NIBR MoA Box Subset
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
Tocriscreen Plus
External IDs
49
Properties
(calculated by RDKit )
Molecular Weight
170.11
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
3
Ring Count
1
Aromatic Ring Count
0
cLogP
-0.13
TPSA
63.4
Fraction CSP3
0.75
Chiral centers
1.0
Largest ring
5.0
QED
0.64
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Voltage-gated N-type calcium channel alpha-1B subunit
mAChR
Synaptic vesicle glycoprotein 2A
Calcium Channel
DNA methyltransferase (DNMT)
CACNA1B, SCN1A, SV2A
Anticonvulsant
AChR,Calcium Channel
Target Type
Cell Biology
Pathway
Neuronal Signaling
GPCR/G protein
Chromatin/Epigenetic
Membrane Transporter/Ion Channel
Metabolism
MOA
synaptic vesicle glycoprotein 2A modulator
calcium channel blocker
Primary Target
Translocation, Exocytosis & Endocytosis
Member status
member
Indication
seizures
Therapeutic Class
Anticonvulsants
Source data